Allogene Therapeutics, Inc. Common Stock (ALLO) Stock Price, Quote & AI Analysis

Live ALLO stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Allogene Therapeutics, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Allogene Therapeutics, Inc. Common Stock (ALLO), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

ALLO
Allogene Therapeutics, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
0.000000
High
0.000000
Low
0.000000
Volume
0
VWAP
-
Market Cap
$413,503,464.96
52W Range
$0.86 - $3.78
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Mar 11, 2026 Q4
After Hours
EPS Estimate: $-0.2182
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Allogene Therapeutics, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Allogene Therapeutics, Inc. Common Stock Overview

Company information

Company Overview

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Company Details
Market Cap
$412.38M
Shares Outstanding
224,730,159
Weighted Shares Outstanding
224,730,144
CEO
David D. Chang
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Employees
361
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Allogene Therapeutics, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...